N8 Medical is a clinical-stage medical device company focused upon commercializing antimicrobial medical devices and coatings to address the multi-billion dollar public health and economic burden associated with medical device-related hospital acquired infections (“HAIs”). N8 Medical’s business is based on the application of a novel, proprietary class of compounds known as ceragenins or CSAs (“ceragenins” or “CSAs”) to medical devices for the purpose of transforming existing medical devices into high value devices with antimicrobial, anti-inflammatory and other therapeutic properties that improve patient outcomes and lower the overall cost of care. In April 2017, FDA granted our request to designate our CeraShield™ drug-eluting endotracheal tube as a "breakthrough device" pursuant to the 21st Century Cures Act.  We expect IDE approval in February 2018.

For more information about N8 Medical, please see www.n8medical.com.

N8 Medical

Org chart

Teams

Offices